Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis in mice

Arai, Iwao; Takaoka, Akiko; Hashimoto, Yuki; Honma, Yusuke; Koizumi, Chie; Futaki, Nobuko; Sugimoto, Masako; Takahashi, Nobutaka; Nakanishi, Yoshinobu; Sakurai, Takanobu; Tanami, Toru; Yagi, Makoto; Ono, Naoya; Nakaike, Shiro

doi:10.1016/j.ejphar.2006.10.064

Cited by 18 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We have intensively analyzed the relationship between chronic itching and prostaglandins [9] and recently showed that the spontaneous scratching behavior of conventional NC/Nga mice was significantly aggravated by the topical application of SC-560 but remained unaffected following that of NS-398 (a COX-2-selective inhibitor), suggesting that COX-1-derived skin PGs might be endogenous inhibitors of itching in NC/Nga mice [10]. Among the COX-1-derived PGs, we speculated that PGD2 might play a central role in this inhibition via its DP1 receptor [31]; however, experiments using smallmolecule inhibitors have generally limitations because of the inhibitors' specificities [9,31]. Thus, the knockdown technique presented in this paper fulfilled its purpose in validating the available evidence regarding which target molecules or receptors might be responsible for the inhibition of itching.…”

Section: Discussionmentioning

confidence: 95%

Modulation of scratching behavior by silencing an endogenous cyclooxygenase‐1 gene in the skin through the administration of siRNA

Sugimoto¹,

Sakurai²,

Saito³

et al. 2007

The Journal of Gene Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

Modulation of scratching behavior by silencing an endogenous cyclooxygenase‐1 gene in the skin through the administration of siRNA

Sugimoto¹,

Sakurai²,

Saito³

et al. 2007

The Journal of Gene Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…DP 1 agonists are not used to treat glaucoma because of the initial ocular hypertensive spike and an unacceptable incidence of ocular surface hyperemia (Nakajima et al, 1991). Perhaps the most promising of the newly advanced medical hypotheses is their potential utility in treating pruritus and atopic dermatitis (Angeli et al, 2004;Arai et al, 2004Arai et al, , 2007Sugimoto et al, 2007). DP 1 receptor antagonists, notably BW A868C, have been available for a long time (Giles et al, 1989).…”

Section: Distribution and Biological Functionsmentioning

confidence: 99%

International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, Updating 15 Years of Progress

Woodward

Jones

Narumiya³

2011

Pharmacol Rev

396

414

View full text Add to dashboard Cite

“…43,44 Many mediating agents are involved in the genesis of the inflammated skin pruritus; histamine is essential, but not the only one: cytokines, prostaglandines, tachykinins, P substance, and others also play a role in the development of the symptom. 45 Another factor is the modulation of sensory nerves in the presentation of antigens and skin inflammation. There is evidence that pruritus is a complex sensation, influenced not only by the intensity of the stimulus or severity of the atopic disease, but also by central neurologic stimuli, according to findings by Heyer et al 46 Studies by Seidenari and Giusti attempted to correlate the degree of pruritus with instrumental measurements of the barrier function; these authors observed a progressive reduction of skin hydration values (corneometry) based on pruritus Enzymatic measurements of the stratum corneum of AD patients compared with contact dermatitis subjects…”

mentioning

confidence: 99%

Barreira cutânea na dermatite atópica

Addor

Aoki

2010

An. Bras. Dermatol.

View full text Add to dashboard Cite

Research about the skin barrier and its properties has increased significantly since the 60s, with studies that indicated its resistance when isolated, as well as its particularities in relation to skin permeability. At the same time, description of Odland bodies helped to understand how stratum corneum stability is maintained. The "brick and mortar" model is the most accepted so far. In this analogy, the corneocytes are the bricks and the intercellular lipids are the mortar. Currently, there is concrete evidence that the stratum corneum is an active metabolic structure that holds adaptive functions, interacting dynamically with the underlying epidermal layers. The skin barrier also plays a role in the inflammatory response through melanocyte activation, angiogenesis, and fibroplasia. The intensity of this response will essentially depend on the severity of the injury. Skin barrier abnormalities in atopic dermatitis are clinically observed by the presence of dry skin, a common and significant symptom which constitutes a diagnostic and monitoring parameter. The stratum corneum hydration level and transepidermal water loss are associated with the level of damage to the barrier, representing biophysical parameters. These parameters help doctors monitor patients in a less invasive and more sensitive manner. Keywords: Dermatitis, atopic; Insensible; Keratinocytes; Water loss Resumo: O estudo da barreira cutânea e de suas propriedades ganhou impulso a partir da década de 60, com estudos que apontaram sua resistência de forma isolada e suas propriedades com relação à permeação cutânea. Paralelamente, a descrição dos corpos de Odland auxiliou a compreensão da manutenção da estabilidade da camada córnea. O modelo brick & mortar, em que os corneócitos são os tijolos e o cimento são os lipídeos intercelulares, é o mais aceito, até o momento. Atualmente, há evidências consistentes de que o estrato córneo é uma estrutura metabolicamente ativa e exerce funções adaptativas. A barreira cutâ-nea também tem um papel na resposta inflamatória, com ativação de melanócitos, angiogênese e fibroplasia, cuja intensidade depende, basicamente, da intensidade da agressão. As anormalidades da barreira cutâ-nea da dermatite atópica são clinicamente observáveis pela presença de pele seca, achado muito frequente e significativo, que constitui parâmetro diagnóstico e de acompanhamento. O grau de hidratação da camada córnea, assim como a perda de água transepidérmica (transepidermal water loss -TEWL), estão relacionados com o grau de dano à barreira, constituindo parâmetros biofísicos que permitem acompanhar os pacientes de maneira não invasiva e com maior grau de sensibilidade. Palavras-chave: Dermatite atópica; Queratinócitos; Perda insensível de água

show abstract

Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis in mice

Cited by 18 publications

References 28 publications

Modulation of scratching behavior by silencing an endogenous cyclooxygenase‐1 gene in the skin through the administration of siRNA

Modulation of scratching behavior by silencing an endogenous cyclooxygenase‐1 gene in the skin through the administration of siRNA

International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, Updating 15 Years of Progress

Barreira cutânea na dermatite atópica

Contact Info

Product

Resources

About